{"id":"NCT01970488","sponsor":"Amgen","briefTitle":"Study to Compare Efficacy and Safety of ABP 501 and Adalimumab (HUMIRA®) in Adults With Moderate to Severe Plaque Psoriasis","officialTitle":"A Phase 3, Multicenter, Randomized, Double-blind Study Evaluating the Efficacy and Safety of ABP 501 Compared With Adalimumab in Subjects With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-10-18","primaryCompletion":"2014-08-14","completion":"2015-03-18","firstPosted":"2013-10-28","resultsPosted":"2016-12-13","lastUpdate":"2019-04-03"},"enrollment":350,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Psoriasis"],"interventions":[{"type":"BIOLOGICAL","name":"Adalimumab","otherNames":["HUMIRA®"]},{"type":"BIOLOGICAL","name":"ABP 501","otherNames":["Adalimumab-atto","AMJEVITA™"]}],"arms":[{"label":"ABP 501","type":"EXPERIMENTAL"},{"label":"Adalimumab","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this research study is to compare the efficacy and safety of ABP 501 and adalimumab (HUMIRA®) in adults with plaque psoriasis.","primaryOutcome":{"measure":"Percent Improvement From Baseline in Psoriasis Area and Severity Index (PASI) at Week 16","timeFrame":"Baseline and Week 16","effectByArm":[{"arm":"Part 1: ABP 501","deltaMin":80.91,"sd":24.237},{"arm":"Part 1: Adalimumab","deltaMin":83.06,"sd":25.195}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":3,"countries":["Australia","Canada","Hungary"]},"refs":{"pmids":["28755394"],"seeAlso":["http://www.amgentrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":174},"commonTop":["Nasopharyngitis","Headache","Upper respiratory tract infection","Arthralgia","Psoriasis"]}}